WHO guidance aims to help regulators identify 'false' biosimilars
This article was originally published in SRA
Executive Summary
The World Health Organization has issued draft guidance on the scientific principles that national regulatory authorities and drug manufacturers should consider for re-evaluating marketed biosimilars that were not licensed in accordance with globally agreed and relevant regulations1.